MedTrace Logo

ARISE - Aggressive Reduction of Inflammation Stops Events

NCT00066898 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 6000

Last updated 2006-10-03

No results posted yet for this study

Summary

To assess the safety and efficacy of AGI-1067, as compared to placebo, in the treatment of vascular inflammation and atherosclerosis by assessing the reduction in cardiovascular events.

Conditions

Interventions

DRUG

AGI-1067

Sponsors & Collaborators

  • AtheroGenics

    lead INDUSTRY

Principal Investigators

  • Marc A Pfeffer, MD · Cardiovascular Division Brigham and Women's Hospital

  • Jean-Claude Tardif, MD · Montreal Heart Institute

  • John McMurray, MD · Western Infirmary

  • Eric Klug, MD · Independent Medical Practitioner - South Africa

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-06-30
Completion
2006-12-31

Countries

  • United States
  • Canada
  • South Africa
  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00066898 on ClinicalTrials.gov